Sex differences in genetics and neurodegenerative and pathophysiologic processes related to AD may partly explain the observed associations, as previous studies have indicated greater amyloid-β burden, tau pathology, and loss of brain volume in females compared to males [6–8]. This evidence concerns the gene MAPT and Alzheimer disease.